Precision Cancer Consortium strengthens its membership with the addition of industry powerhouse

The Precision Cancer Consortium (PCC) has bolstered its membership with the addition of Bristol Myers Squibb (BMS), reinforcing its mission to drive collaboration and expand global patient access to comprehensive genomic profiling (CGP) in both routine care and clinical trials. The PCC is composed of seven pharmaceutical companies – AstraZeneca, Bayer, Bristol Myers Squibb, Johnson & Johnson, Lilly, Novartis, and Roche – each with a shared goal of making precision oncology and CGP the new normal.

Jilian Golding, Global Commercial Strategy Precision Medicine Lead, BMS said about the company’s decision to join the PCC, “We are excited to join the PCC and help expand its impact, building on the momentum the group has established with improving patient access to quality biomarker testing. These improvements are a critical step towards ensuring healthcare professionals have the information they need to best inform optimal management decisions.”

Pictured: Jilian Golding, PCC Board Member and Global Commercial Strategy Precision Medicine Lead, BMS.

Gabriele Allegri, PCC Chair and Vice President for Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine, also shared his enthusiasm for BMS joining the consortium, highlighting that “their expertise will be invaluable as we collaborate to advance precision oncology and expand access to CGP. Together, we are working to make these innovations the standard of care, so that more patients receive the right care at the right time, improving outcomes and transforming lives.”

Pictured: Gabriele Allegri, PCC Chair and Vice President for Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine.

From the PCC’s inception in 2022, the consortium seeks to increase patient access to CGP in both routine care and research on a global scale, educate stakeholders and increase awareness on how CGP can improve patient outcomes, and address the challenges of implementing CGP in healthcare systems to improve equitable access to testing. At the American Society of Clinical Oncology (ASCO) 2025 conference in May, the PCC was thrilled to celebrate its Wayfinders – the members and partner organizations who rely on their inner strategic compass to drive the success of PCC’s initiatives, ensuring impactful delivery of projects that improve patient outcomes, including:

  • Developing strategies and forging partnerships to advance local adoption of liquid biopsy technologies
  • Launching a new initiative to broaden the use of CGP for patients with solid tumors, beginning at diagnosis
  • Introducing the latest version of the genomic testing cost calculator – a dynamic tool that illustrates cost differences between next-generation sequencing (NGS), other multiplex diagnostics, and traditional single-gene testing (SGT) across the EU
  • Collaborating with the Institute for Clinical Effectiveness and Health Policy (IECS) and the London School of Economics and Political Science (LSE) to establish a European CGP value framework that promotes transparent, objective, and patient-centred decision-making in cancer care

About the PCC

The Precision Cancer Consortium is composed of pharmaceutical and biotechnology companies focused on fostering collaboration on issues and opportunities related to precision oncology with the goal of improving patient outcomes by increasing access to comprehensive genomic testing, including next generation sequencing, and addressing major gaps in precision diagnostics availability.

Enquiries about PCC membership can be submitted via the Membership Enquiries page here.

PCC-214 | October 2025